MRNA Stock, Moderna Inc. Information

Marina Biotech, Inc. is a fully integrated, commercial stage biopharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and additional markets. Our portfolio of products focuses on fixed dose combinations FDC in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our approach is meant to reduce clinical risk and accelerate time to market by shortening the clinical development program through leveraging what is already known or can be learned in our proprietary Patient Level Database. We currently have one commercial and three clinical development programs underway: i Prestalia , a single pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S. ii our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT and IT , each of which is an FDC of celecoxib and either lisinopril IT or olmesartan IT iii CEQ , an oral delivery of small interfering RNA against beta catenin, combined with IT to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis and iv CEQ combined with IT to treat Colorectal Cancer.